Earnings summaries and quarterly performance for Jade Biosciences.
Research analysts covering Jade Biosciences.
Recent press releases and 8-K filings for JBIO.
Jade Bio Provides Pipeline and Financial Updates at Oppenheimer Conference
JBIO
New Projects/Investments
Guidance Update
- Jade Bio's lead program, JADE101, an anti-APRIL for IgA nephropathy, is expected to have a Phase I healthy volunteer trial readout in the first half of 2026, with a Phase 2 initiation planned for mid-2026 and interim data in 2027.
- The company believes JADE101 has the potential to be a best-in-class agent for IgA nephropathy, citing its superior potency and design for a convenient dosing interval of no more frequent than one subcutaneous injection every 8 weeks.
- Jade Bio's second program, JADE201, an anti-BAFF-R for broad autoimmune diseases, is scheduled to initiate its first-in-human trial in Q2 2026 with data expected in 2027.
- The company reported a strong financial position with $336 million in cash at the end of 2025, providing a cash runway into the first half of 2028.
1 day ago
Jade Biosciences Provides Update on Clinical Programs and Financial Position
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences is advancing three clinical programs for autoimmune diseases, with its lead candidate, JADE101, an anti-APRIL therapeutic for IgA nephropathy, expected to have Phase I healthy volunteer trial readout in the first half of 2026.
- JADE101 aims to be a best-in-class treatment for IgA nephropathy, a market estimated at over $10 billion in the U.S. alone, due to its superior potency and potential for once every 8-week subcutaneous dosing.
- The company plans to initiate a Phase II trial for JADE101 in mid-2026, with interim data anticipated in 2027.
- Its second program, JADE201 (anti-BAFF-R), is slated for first-in-human initiation in Q2 2026, with data expected in 2027, and a third program, JADE301, is projected to enter the clinic in H1 2027.
- Jade Biosciences ended 2025 with $336 million in cash, providing a financial runway into the first half of 2028 to support these milestones.
1 day ago
Jade Biosciences Provides Update on Therapeutic Pipeline and Financial Position
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences is focused on developing best-in-class therapeutics for autoimmune diseases, with three programs in its pipeline.
- The lead program, JADE101, an anti-APRIL for IgA nephropathy, is currently in a Phase I healthy volunteer trial with a readout expected in the first half of 2026. A Phase II trial is planned for initiation in mid-2026, with interim data anticipated in 2027.
- JADE101 is designed to be a potential best-in-class agent, demonstrating femtomolar potency and being over 750-fold more potent than sibeprenlimab. The company aims for a dosing interval of no more frequent than one subcutaneous injection every eight weeks. The IgA nephropathy market opportunity is estimated to be over $10 billion in the U.S. alone.
- The second program, JADE201, an anti-BAFF-R, is slated to initiate its first-in-human trial in Q2 2026, with data expected in 2027.
- Jade Biosciences closed 2025 with $336 million in cash, which is projected to fund operations into the first half of 2028.
1 day ago
Jade Biosciences Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
JBIO
New Projects/Investments
Guidance Update
Product Launch
- Jade Biosciences, launched in mid-2024, is focused on developing best-in-class therapeutics for autoimmune diseases, with three programs in its pipeline.
- The lead program, Jade 101 (anti-APRIL for IgA nephropathy), completed Phase 1 enrollment last year and expects data disclosure in H1 2026, with plans to dose the first patient in Phase 2 around mid-2026 and data in 2027. This program aims for best-in-class efficacy and Q8 week dosing, targeting a U.S. IgA nephropathy market opportunity initially estimated at $10 billion+, which some analysts now suggest could be $40 billion.
- Jade 201 (anti-BAFF receptor) is scheduled to begin a Phase 1 first-in-human study in Q2 2026, with data anticipated in 2027. A third, undisclosed program is expected to enter the clinic in H1 2027.
- The company closed last year with $336 million in capital, providing funding for operations across its three programs into H1 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Updates on Autoimmune Pipeline and Market Opportunity at J.P. Morgan Healthcare Conference
JBIO
Product Launch
New Projects/Investments
Guidance Update
- Jade Biosciences, launched in mid-2024, is advancing a pipeline of three autoimmune disease therapeutics, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), expecting Phase I data in the first half of 2026 and Phase II dosing by mid-2026.
- JADE101 aims for best-in-class efficacy and a convenient Q8 week dosing schedule, targeting a rapidly expanding IgA nephropathy market estimated at $10 billion-plus in the U.S. alone, with some analysts projecting up to $40 billion.
- The company's second program, JADE201 (anti-BAFF receptor), is scheduled to begin Phase I in Q2 2026, and a third undisclosed program is expected to enter the clinic in the first half of 2027.
- Jade Biosciences reported $336 million in capital at the end of 2025, sufficient to fund operations for its three programs into the first half of 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Outlines Clinical Development and Financial Runway
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences, launched in mid-2024, is focused on developing best-in-class therapeutics for autoimmune diseases.
- Its lead program, Jade 101 for IgA nephropathy, completed Phase 1 enrollment in 2025, with data expected in H1 2026 and Phase 2 patient dosing planned for mid-2026. The U.S. market opportunity for IgA nephropathy is estimated at $10 billion-plus, with some analysts suggesting $40 billion.
- The second program, Jade 201, an anti-BAFF receptor, is scheduled to begin a Phase 1 first-in-human study in Q2 2026, with data anticipated in 2027.
- The company reported $336 million in capital at the end of 2025, sufficient to fund operations for its three programs into the first half of 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Outlines 2026 Objectives and Pipeline Strategy
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences expects to have approximately $336 million in cash, cash equivalents, and investments as of December 31, 2025, which is anticipated to fund operations into the first half of 2028.
- The company anticipates interim Phase 1 data for JADE101 in the first half of 2026 and expects to initiate a Phase 2 clinical trial for JADE101 in IgA nephropathy mid-2026.
- JADE201 is expected to begin a first-in-human study in rheumatoid arthritis patients in the second quarter of 2026, and JADE301 is expected to commence a Phase 1 clinical trial in the first half of 2027.
Jan 5, 2026, 12:17 PM
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. announced a private placement financing expected to generate approximately $45 million in gross proceeds.
- The company is selling 3,214,286 shares of its common stock at a price of $14.00 per share to BB Biotech.
- The private placement is expected to close on or about December 16, 2025.
- Net proceeds from the offering will be used to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:11 PM
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. (JBIO) has entered into a securities purchase agreement with BB Biotech for a private placement financing, expected to generate approximately $45 million in gross proceeds.
- The company is selling an aggregate of 3,214,286 shares of its common stock at a purchase price of $14.00 per share.
- The private placement is anticipated to close on or about December 16, 2025, subject to customary closing conditions.
- The net proceeds from this financing are intended to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:00 PM
Jade Management Discusses Clinical Pipeline and IgA Nephropathy Market
JBIO
New Projects/Investments
Product Launch
Guidance Update
- Jade (JBIO), founded in June 2024, is developing three assets, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), having initiated a Phase I study in August 2025 and expecting a key readout in H1 2026.
- The company's pipeline includes JADE201 (targeting BAFF-R) anticipated to enter the clinic in H1 2026, and a third undisclosed program in H1 2027.
- Jade is well-resourced to fund all trials into H1 2028.
- Management views IgA nephropathy as a a $10 billion+ opportunity in the US alone, emphasizing the disease-modifying potential of anti-APRIL therapies and the importance of convenience through infrequent dosing for JADE101.
- The FDA is considering shortening eGFR confirmatory trials for iGAN from two years to one year, which could support efficient development of anti-APRIL mechanisms.
Nov 17, 2025, 3:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more